¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Gene Expression Regulation, Leukemic"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • regulatory gene
    Á¶ÀýÀ¯ÀüÀÚ
  • reporter gene
    Á¤º¸Á¦°øÀ¯ÀüÀÚ
  • repressor gene
    ¾ïÁ¦À¯ÀüÀÚ
  • retinoblastoma gene
    ¸Á¸·¸ð¼¼Æ÷Á¾À¯ÀüÀÚ
  • structural gene
    ±¸Á¶À¯ÀüÀÚ
  • suicide gene
    ÀÚ»ìÀ¯ÀüÀÚ
  • suppressor gene
    ¾ïÁ¦À¯ÀüÀÚ
  • single major gene locus model
    ´ÜÀÏÁÖ¿äÀ¯ÀüÀÚÀÚ¸®¸ðÇü
  • single-gene disorder
    ´ÜÀÏÀ¯ÀüÀÚÁúȯ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • retinoblastoma gene
    ¸Á¸·¸ð¼¼Æ÷Á¾À¯ÀüÀÚ
  • structural gene
    ±¸Á¶À¯ÀüÀÚ
  • suicide gene
    ÀÚ»ìÀ¯ÀüÀÚ
  • supressor gene
    ¾ïÁ¦À¯ÀüÀÚ
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • single major gene locus model
    ´ÜÀÏÁÖ¿äÀ¯ÀüÀÚÀÚ¸®¸ðÇü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • control gene
    Á¦¾îÀ¯ÀüÀÚ(ð¤åÙë¶îîí­).
  • covering gene
    ÇǺ¹À¯ÀüÀÚ(¡­ë¶îîí­).
  • dcc gene
    DCC À¯ÀüÀÚ(¡­ë¶îîí­)
  • determinant gene
    °áÁ¤À¯ÀüÀÚ(̽ïÒë¶îîí­).
  • dominant autosomal gene
    ¿ì¼ºº¸Åë¿°»öüÀ¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ(¡­ë¶îîí­).
  • dominant gene
    ¿ì¼ºÀ¯ÀüÀÚ(éÐàõë¶îîí­).
  • dq3.2 gene
    DQ3.2 À¯ÀüÀÚ(¡­ë¶îîí­)
  • duplicate gene
    º¹»çÀ¯ÀüÀÚ.
  • exaggeration gene
    °­Á¶À¯ÀüÀÚ(¡­ë¶îîí­).
  • familial colon carcinoma gene
    °¡Á·¼º ´ëÀå¾ÏÁ¾ À¯ÀüÀÚ
  • fmr-1 gene
    FMR-1 À¯ÀüÀÚ
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene
    À¯Àü(ÀÎ)ÀÚ(ë¶îîì×í­).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • MIT gene
    MIT À¯ÀüÀÚ(ë¶îîí­)
  • modification gene
    ¼ö½ÄÈ¿¼Ò À¯ÀüÀÚ(áóãÞý£áÈë¶îîí­)
  • modifying gene
    ¼ö½ÄÀ¯ÀüÀÚ(áóãÞë¶îîí­)
  • morphogenetic gene
    ÇüÅÂÇü¼ºÀ¯ÀüÀÚ(û¡÷¾û¡à÷ë¶îîí­)
  • morphopoietic gene
    ÇüÅÂÀ¯ÀüÀÚ(û¡÷¾ë¶îîí­)
  • multiple gene
    ´ÙÀ¯ÀüÀÚ(Òýë¶îîí­)
  • mutable gene
    °¡º¯ÀÌÀ¯ÀüÀÚ(ʦܨì¶ë¶îîí­)
  • mutant gene
    º¯ÀÌÀ¯ÀüÀÚ(ܨì¶ë¶îîí­)
  • mutator gene
    º¯ÀÌÀÚ À¯ÀüÀÚ(ܨì¶í­ë¶îîí­)
  • negative gene control
    À½À¯ÀüÀÚÁ¦¾î(ëäë¶îîí­ð¤åÙ)
  • nif gene
    nif À¯ÀüÀÚ(ë¶îîí­)
  • nonessential gene
    ºñÇʼöÀ¯ÀüÀÚ(Þªù±áóë¶îîí­)
  • one-gene-one-enzyme hypothesis
    ÀÏÀ¯ÀüÀÚÀÏÈ¿¼Ò¼³(ìéë¶îîí­ìéý£áÈàã)
  • one-gene-one-polypeptide chain hypothesis
    ÀÏÀ¯ÀüÀÚ(ìéë¶îîí­) ÀÏ(ìé)Æú¸®ÆéŸÀÌµå »ç½½¼³(àã)
  • open gene
    ¿­¸° À¯ÀüÀÚ(ë¶îîí­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
GTA gene transfer agent; Glanzmann thrombasthenia; glycerol teichoic acid
HGM hog gastric mucosa; human gene mapping; human glucose monitoring
HPR haptoglobin-related gene; health practices research
hsp heat shock protein [gene]
hut histidine utilization [gene]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CagA Cytotoxin-associated gene A
Ddc DOPA decarboxylase gene
EGR1 early growth response 1 gene
EDG Endothelial differentiation gene
FMR1 Fragile X Mental Retardation gene 1
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
gene mapping Determination of the relative positions of genes on a DNA molecule (chromosome or plasmid) and of the distance, in linkage units or physical units, between them.
(09 Oct 1997)
gene markers Detectable genetic traits or distinctive segments of DNA that serve as landmarks for a target gene. Markers are on the same chromosome as the target gene. They must be near enough to the target gene to be genetically linked to it: to be inherited usually together with that gene, and so serve as signposts to it.
(12 Dec 1998)
gene mosaicism <genetics> Descriptive of an organism that consists of two or more genetically distinct cell lines.
(14 Nov 1997)
gene pool The total sum of genetic information present in a population at anygiven moment.
(09 Oct 1997)
gene probe A biomolecule that islabelled with radioactive isotopes or with a fluorescent marker that selectively binds to a specific gene so it can be isolated or identified.
(09 Oct 1997)
gene product The biochemical material, either RNA or protein, resulting from expression of a gene. The amount of gene product is used to measure how active a gene is, abnormal amounts can be correlated with disease-causing alleles.
(09 Oct 1997)
gene products, env Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease.
(12 Dec 1998)
gene products, gag Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen.
(12 Dec 1998)
gene products, nef Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor.
(12 Dec 1998)
gene products, pol Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase.
(12 Dec 1998)
gene products, rev Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion.
(12 Dec 1998)
gene products, rex Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr.
(12 Dec 1998)
gene products, tat Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription.
(12 Dec 1998)
gene products, tax Transcriptional trans-acting proteins of the promoter elements found in the long-terminal repeats (ltr) of HTLV-I and HTLV-II. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the ltr.
(12 Dec 1998)
gene products, vif A 23 kD regulatory protein important for virion infectivity in HIV. The protein is found in the cytoplasm of HIV-infected cells and is not absolutely required for virion formation.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á